Mikhail Melnik
University of California, Los Angeles
6 Papers
6 Citations
Mikhail Melnik is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: LRP1 & Synaptic vesicle. The author has an hindex of 2, co-authored 6 publications.
Chat about Author
Papers
Pharmacological inhibition of nSMase2 reduces brain exosome release and α-synuclein pathology in a Parkinson's disease model.
Chunni Zhu,Tina Bilousova,Samantha Focht,Michael Jun,Chris Jean Elias,Mikhail Melnik,Sujyoti Chandra,Jesus Campagna,Whitaker Cohn,Asa Hatami,Patricia Spilman,Karen H. Gylys,Varghese John +12 more
TL;DR: In this paper, Cambinol (DDL112) was shown to suppress extracellular vesicle (EV)/exosome production in vitro in a cell model and reduced tau seed propagation.
Correction to: Pharmacological inhibition of nSMase2 reduces brain exosome release and α-synuclein pathology in a Parkinson's disease model.
Exosomal tau with seeding activity is released from Alzheimer's disease synapses, and seeding potential is associated with amyloid beta.
Emily Miyoshi,Tina Bilousova,Mikhail Melnik,Danyl Fakhrutdinov,Wayne W. Poon,Harry V. Vinters,Carol A. Miller,Maria M. Corrada,Claudia H. Kawas,Ryan C. Bohannan,Chad A. Caraway,Chris Jean Elias,Katherine N. Maina,Jesus Campagna,Varghese John,Karen H. Gylys +15 more
TL;DR: In this article, a flow cytometry assay was used to quantify depolarization of synaptosomes by KCl after loading with FM2-10, which induces a fluorescence reduction associated with synaptic vesicle release.
1
Analysis of cell-type specific exosomes isolated from cryopreserved human brain
Tina Bilousova,Mikhail Melnik,Whitaker Cohn,Calvin Huang,Bruce Teter,Varghese John,Karen H. Gylys +6 more
TL;DR: Ability of brain exosomes to cross the blood brain barrier make them a potential diagnostic and monitoring tool for Alzheimer’s disease treatment.
1
Dual Neutral Sphingomyelinase-2/Acetylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease.
Tina Bilousova,Bryan J. Simmons,Rachel R. Knapp,Chris Jean Elias,Jesus Campagna,Mikhail Melnik,Sujyoti Chandra,Samantha Focht,Chunni Zhu,Kanagasabai Vadivel,Jagodzinska Barbara,Whitaker Cohn,Patricia Spilman,Karen H. Gylys,Neil K. Garg,Varghese John +15 more
TL;DR: Identification of these novel dual nSMase2/AChE inhibitors represents a new therapeutic approach to AD and has the potential to lead to the development of truly disease-modifying therapeutics.